Harrow Announces First Quarter 2026 Financial Results
Harrow reported Q1 2026 revenue of $44.2 million, a 7.6% decline from the prior year, primarily due to a non-recurring gross-to-net revenue adjustment of approximately $8 million. Despite the revenue decline, the company remains on track to meet its 2026 revenue guidance of $350 million to $365 million, with strong demand for its key products. VEVYE delivered record prescription performance, surpassing XIIDRA on a monthly total prescription basis and achieving a 14% market share as of the end of March 2026.
Key figures
- Revenue
- 44203000
- Guidance
- Q2 revenue expected between $71 million and $81 million; full-year 2026 revenue guidance reaffirmed at $350 million to $365 million
- Revenue Yoy
- -7.6%
- Gross margin
- 61%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.